The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia
- PMID: 30222710
- DOI: 10.1097/FPC.0000000000000352
The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia
Abstract
Objective: Methotrexate (MTX) is an important drug in the treatment of pediatric acute lymphoblastic leukemia (ALL). MTX is cytotoxic as it impairs DNA and RNA synthesis by inhibiting the enzymes dihydrofolate reductase (DHFR) and thymidylate synthase (TYMS). The association between genetic variants within the TYMS gene and MTX-induced toxicity has been studied, but results are inconsistent. We determined the role of three previously described variants within the TYMS gene and MTX-induced oral mucositis in a prospective cohort of Dutch children with ALL and performed a meta-analysis of the previous results.
Materials and methods: We analyzed the presence of a 28-base pair tandem repeat (rs34743033; 2R3R), a single nucleotide polymorphism present within the 28-base pair repeat on the 3R allele (rs2853542; 3RG>C) and a 6-base pair deletion (rs15126436; TTAAAG) within the TYMS gene in germline DNA of 117 pediatric patients with ALL. Oral mucositis was defined as grade≥3 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v.3.0. Data were analyzed for the individual rs34743033 (2R3R) and rs151264360 (6 bp deletion) polymorphisms, whereas rs2853542 (3RG>C) was combined with rs34743033 (2R3R) and analyzed according to predicted expression levels of TYMS: low expression (2R/2R, 2R/3RC and 3RC/3RC), median expression (2R/3RG and 3RC/3RG) and high expression (3RG/3RG). We performed a meta-analysis of the current literature on these polymorphisms in relation to oral mucositis using a fixed effects model.
Results: The 2R2R genotype (rs34743033) was not significantly associated with developing MTX-induced oral mucositis compared with the 2R3R/3R3R genotypes, which was confirmed in a meta-analysis [odds ratio (OR): 1.17 (0.62-2.19)]. Patients carrying the low-expression TYMS genotype (2R2R, 2R3RC, 3RC3RC) had an increased odds of developing MTX-induced oral mucositis [OR: 2.42 (0.86-6.80)], which did not reach statistical significance. The 6-bp deletion [rs151264360, OR: 0.79 (0.20-3.19)] was not associated with the development of MTX-induced oral mucositis.
Conclusion: The TYMS 6-bp deletion and 2R3R polymorphism were not associated with MTX-induced oral mucositis. Validation studies in prospective cohorts are necessary to assess the possible role of the low-expression TYMS genotypes in relation to MTX-induced oral mucositis.
Similar articles
-
Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents.Cancer Chemother Pharmacol. 2005 Nov;56(5):465-72. doi: 10.1007/s00280-005-1018-z. Epub 2005 May 26. Cancer Chemother Pharmacol. 2005. PMID: 15918040
-
Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia.Cancer Chemother Pharmacol. 2021 Mar;87(3):379-385. doi: 10.1007/s00280-020-04197-8. Epub 2020 Nov 10. Cancer Chemother Pharmacol. 2021. PMID: 33170323
-
Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients.PLoS One. 2014 Oct 3;9(10):e108165. doi: 10.1371/journal.pone.0108165. eCollection 2014. PLoS One. 2014. PMID: 25279663 Free PMC article.
-
G>C SNP of thymidylate synthase with respect to colorectal cancer.Pharmacogenomics. 2007 Aug;8(8):985-96. doi: 10.2217/14622416.8.8.985. Pharmacogenomics. 2007. PMID: 17716232 Review.
-
The effect of leucovorin rescue therapy on methotrexate-induced oral mucositis in the treatment of paediatric ALL: A systematic review.Crit Rev Oncol Hematol. 2019 Oct;142:1-8. doi: 10.1016/j.critrevonc.2019.07.003. Epub 2019 Jul 9. Crit Rev Oncol Hematol. 2019. PMID: 31323533
Cited by
-
Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic Leukemia.Pharmgenomics Pers Med. 2020 Aug 12;13:295-317. doi: 10.2147/PGPM.S239602. eCollection 2020. Pharmgenomics Pers Med. 2020. PMID: 32848445 Free PMC article. Review.
-
Impact of microRNA polymorphisms on high-dose methotrexate-related hematological toxicities in pediatric acute lymphoblastic leukemia.Front Pediatr. 2023 Jun 13;11:1153767. doi: 10.3389/fped.2023.1153767. eCollection 2023. Front Pediatr. 2023. PMID: 37384310 Free PMC article.
-
Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.Genes (Basel). 2020 Apr 24;11(4):468. doi: 10.3390/genes11040468. Genes (Basel). 2020. PMID: 32344632 Free PMC article.
-
Gene Polymorphisms Involved in Folate Metabolism and DNA Methylation with the Risk of Head and Neck Cancer.Asian Pac J Cancer Prev. 2020 Dec 1;21(12):3751-3759. doi: 10.31557/APJCP.2020.21.12.3751. Asian Pac J Cancer Prev. 2020. PMID: 33369477 Free PMC article.
-
Astaxanthin Co-treatment with Low Dose Methotrexate Increases the Cell Cycle Arrest and Ameliorates the Methotrexate-induced Inflammatory Response in NALM-6.Int J Mol Cell Med. 2024;13(2):133-146. doi: 10.22088/IJMCM.BUMS.13.2.133. Int J Mol Cell Med. 2024. PMID: 39184820 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases